Paradigm Biopharmaceuticals (ASX:PAR) Net Margin %: -92,976.00% (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Net Margin %?

Paradigm Biopharmaceuticals ASX:PAR -5.88% 28 Net Margin % is -92,976.00% as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 97.78% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Paradigm Biopharmaceuticals's Net Income for the six months ended in Dec. 2025 was A$-23.24 Mil. Paradigm Biopharmaceuticals's Revenue for the six months ended in Dec. 2025 was A$0.03 Mil. Therefore, Paradigm Biopharmaceuticals's net margin for the quarter that ended in Dec. 2025 was -92,976.00%.

The historical rank and industry rank for Paradigm Biopharmaceuticals's Net Margin % or its related term are showing as below:

ASX:PAR' s Net Margin % Range Over the Past 10 Years
Min: -163319.05   Med: -88868.18   Max: -36098.08
Current: -60151.67

ASX:PAR's Net Margin % is ranked worse than
97.78% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs ASX:PAR: -60151.67

Paradigm Biopharmaceuticals  (ASX:PAR) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Paradigm Biopharmaceuticals Net Margin % Related Terms

Paradigm Biopharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Net Margin % Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163,319.05 -49,683.54 -110,446.81 -88,868.18 -36,098.08

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -34,847.06 -36,705.71 -92,976.00

ASX:PAR vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Net Margin % falls into.


ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Paradigm Biopharmaceuticals's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-18.771/0.052
=-36,098.08 %

Paradigm Biopharmaceuticals's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-23.244/0.025
=-92,976.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -92,976.00% mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Net Margin % of -92,976.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #926 out of 947 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Paradigm Biopharmaceuticals' Net Margin % too high?
Paradigm Biopharmaceuticals' current Net Margin % is -92,976.00%. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #926 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #926 out of 947 companies for Net Margin %. This places Paradigm Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Net Margin % is -92,976.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Net Margin % of -92,976.00%. The current Net Margin % is -92,976.00%. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Net Margin % is -92,976.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price